There are no primary remedies for TBI.

Clazosentan drug shows promise against TBI in rats A new drug is showing promise in shielding against the harmful ramifications of traumatic brain injury in rats, according to a study that was released today and you will be presented at the American Academy of Neurology’s 64th Annual Meeting in New Orleans April 21 to April 28, 2012. There are no primary remedies for TBI, which means this extensive research provides hope that effective treatments could be developed, said study writer Michael Kaufman, a second year medical student at Wayne Condition University School of Medicine in Detroit and an associate of the American Academy of Neurology.The researchers found that 3q26.2 rearrangements emerged during all phases of CML, with 33 percent occurring during chronic phase, 17 percent in acute stage and 50 percent in blast phase, but patients whose rearrangement occurred through the chronic or acute stage had a high price of transformation to the blast phase. TKI therapy was given to 82 percent of individuals with chromosome 3 abnormalities with adjustable response, the experts observe. Just three of the 47 individuals with 3q26.2 rearrangements achieved a complete cytogenetic response ; this was transient in two situations and relapse happened after 12 a few months in the 3rd patient.